Bicara Therapeutics (BCAX) analyst forecast and price target
Analyst forecast
Consensus of 16 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BMO Capital | Initiated Coverage | Outperform | $35.00 | Aug 19, 2026 |
| BTIG | Maintained | Buy | $39.00 from $28.00 | Aug 12, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $23.00 from $16.00 | Aug 12, 2026 |
| Mizuho | Maintained | Neutral | $20.00 from $18.00 | Aug 12, 2026 |
| Morgan Stanley | Maintained | Overweight | $39.00 from $37.00 | Aug 12, 2026 |
| Wedbush | Maintained | Outperform | $33.00 from $30.00 | Aug 12, 2026 |
| Goldman Sachs | Maintained | Neutral | $20.00 from $18.00 | Aug 12, 2026 |
| Morgan Stanley | Maintained | Overweight | $37.00 from $36.00 | May 12, 2026 |
| Goldman Sachs | Maintained | Neutral | $18.00 from $16.00 | May 12, 2026 |
| Guggenheim | Initiated Coverage | Buy | $42.00 | May 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $42.00 from $40.00 | Mar 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $16.00 from $11.00 | Mar 31, 2026 |
| Wedbush | Maintained | Outperform | $30.00 | Mar 31, 2026 |
| Goldman Sachs | Maintained | Neutral | $16.00 from $14.00 | Mar 31, 2026 |
| Citizens | Maintained | Market Outperform | $31.00 | Mar 31, 2026 |
| B of A Securities | Initiated Coverage | Buy | $35.00 | Mar 25, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $31.00 | Jan 29, 2026 |
| Wedbush | Maintained | Outperform | $30.00 | Jan 13, 2026 |
| BTIG | Initiated Coverage | Buy | $28.00 | Jan 8, 2026 |
| Mizuho | Initiated Coverage | Neutral | $18.00 | Dec 18, 2025 |
Frequently asked questions
What is the price target for BCAX stock?
The average 12-month analyst price target for Bicara Therapeutics (BCAX) is $29.86, with a high estimate of $39.00 and a low of $20.00, across 7 analysts.
Is BCAX a buy, sell, or hold?
Analysts covering Bicara Therapeutics currently average a Buy rating: 13 buy, 3 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BCAX?
The average price target of $29.86 implies 29.14% upside from the last price of $23.12.
What is the latest analyst rating on BCAX?
On Aug 19, 2026, BMO Capital initiated coverage of Bicara Therapeutics at Outperform with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.